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ILLNESS IMPACT AND ADJUSTMENT TO PARKINSON'S DISEASE:
BEFORE AND AFTER TREATMENT WITH TOLCAPONE
There is evidence that adjustment to chronic illnesses
such as Parkinson's disease (PD) may be affected by
psychological factors especially how patients appraise and
cope with the stress of their illness. There has been
limited research available examining the role of illness
impact or appraisal in adjustment to chronic illness. No
studies were found dealing with the inter-relationship of
illness impact, adjustment and pharmacological treatment.
The purpose of this study was to determine whether the
quality of life (as conceptualized by impact of illness and
adjustment) was improved by treatment with tolcapone in
persons with Parkinson's disease. This study was done in
parallel with a double-blind placebo controlled study of the
efficacy and safety of tolcapone.
Quality of life was measured by the Sickness Impact
Profile (SIP) and adjustment to Parkinson's disease by the
Psychosocial Adjustment to Illness Scale (PAIS-SR).
Illness impact and adjustment to Parkinson's disease
were improved across all treatment groups when compared to
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patients who received placebo. Total illness impact was
significantly improved (p = .003), physical illness impact
was significantly improved (p = .05) and psychosocial
illness impact was significantly improved (p = .007) in
patients who received tolcapone when compared to placebo.
Adjustment to illness was not significantly different
in the tolcapone group when compared to patients receiving
placebo, however a dose related improvement response was
found.
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CHAPTER I
INTRODUCTION
Parkinson's Disease (PD), a chronic, degenerative,
neurologic condition affects approximately 1% of the aged
population. Parkinson's Disease is characterized by loss of
neurons in the substantia nigra and other pigmented nuclei
(Langston, Roller and Giron, 1992). Death of these
specialized cells results in striatal dopamine deficiency,
the primary neurochemical lesion of PD. Symptoms of
idiopathic PD, the most common of the akinetic-rigid
syndromes, include tremor, poverty of movement

(akinesia),

slowness and fatiguing (bradykinesia), postural instability
and rigidity (Weiner and Lang, 1989) .
The complexity of motor dysfunction characteristic of
Parkinson's Disease results in diminution of many aspects of
movement. These impairments have far reaching consequences
which affect independent activities of daily living,
employment, role fulfillment, self concept and a myriad of
interpersonal interactions. The decline in functional

1
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ability in PD can change robust and strong individuals into
stooped and frail ones. PD can change confident and
independent persons into depressed and dependent ones, or
persons who were bright and alert can become apathetic and
listless. The social burden of Parkinson's Disease symptoms
is a heavy one. For the individual with this diagnosis,

life

is fraught with frustration, embarrassment and loneliness
(Koller, 1987). Because of its progressive nature, PD
eventually results in varying degrees of loss of an
individual's independent functional ability. Adjustment to
such changes presents the patient and family with enormous
challenges.
The unique manner in which individuals and families
deal with the demands of this progressive illness influences
the degree and nature of lifelong adjustment and well-being.
Though it is not possible to reverse the physical changes
resulting from Parkinson's Disease, cognitive appraisal of
the threat and personal resources may help to moderate the
impact of the illness

(Miller, 1992). Coping with the

everyday problems that face individuals with Parkinson's
Disease may be the greatest challenge (Hutton & Dipel,
1989) .
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Effective coping strategies utilized by individuals
with Parkinson's Disease are critical to successful
adjustment to this disabling disease. Learning to cope with
an illness such as Parkinson's Disease requires great
determination and a positive attitude (Crary & Waters,
1989) . Coping however may be linked to the individuals
cognitive appraisal of the illness as a threat. Little is
known about Parkinson patients' appraisal of this diagnosis
as a threat or the impact this diagnosis and its'symptoms
have on the individual or their families' functioning.
We are largely ignorant of how patients see themselves
as having changed for better or for worse by their illness
or its' treatment methods. The mediating factors that act as
buffers against psychological distress and how the patient's
social environment affects and is affected by illness needs
further study (Dakof & Mendelsohn, 1984).
In order for nurses to assist patients and family
members to successfully optimize the quality of their life
experiences,

it is critical to understand the impact of this

illness. Despite the multiple medical problems associated
with PD, the basic human needs of the patient must be met
effectively if a successful process of adjustment and
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rehabilitation is to be achieved. The challenge to nursing,
medicine and pharmacological therapy is to sustain a quality
of life through moderation of physical symptoms, while
maintaining and sustaining personal and family function and
relationships which provide support and nurture effective
adaptive processes.
The mainstay pharmacological treatment for Parkinson's
Disease is a form of replacement therapy, a levodopa/
carbidopa (L-dopa) combination which reduces disease
symptoms by chemically replacing the neurotransmitter
dopamine. However, despite pharmacological treatment, a
steady decline in motor function inevitably ensues. Long
term therapy with levodopa eventually results in diminished
efficacy, dose-related motor fluctuations and the
development of side effects. Though treatment with
L-dopa decreases mortality and subdues motor symptoms, it
does not reverse the decline in social functioning (Koller,
1987) .
Recent interaction studies of levodopa in healthy
volunteers have suggested that a new medication, tolcapone,
when given together with levodopa, may result in the need
for lower doses of levodopa, and provide prolonged efficacy
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of levodopa and potentially fewer side effects. Although
there exists partially effective drug therapy for the
symptoms of PD, the length and quality of the PD patient's
life also depends on the maintenance of social and role
fulfillment. Patients' quality of life and adaptation are
clearly affected by both the disease and its treatment
(Fitzsimmons and Bunting, 1993).
There currently exists an abundance of literature
describing the effect of pharmacological and surgical
interventions on motor and depressive symptoms in patients
with Parkinson's Disease. There is also a large body of
conceptual nursing knowledge concerning the impact of
chronic illnesses. However, relatively few investigators
have dealt with the psychosocial aspects of living with PD.
Even less attention has been paid to the interaction of
pharmacological treatment, functional ability, illness
impact and adjustment (Levin & Weiner, 1987).
For a comprehensive understanding of Parkinson's
Disease, we need to broaden our perspective on this illness
to "include the psychosocial aspects which may provide
buffers against both the physical and psychological
stressors imposed by chronic illness"

(Dakof & Mendelsohn,
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1986, p. 3 85). To determine such a perspective includes
understanding how an individual patient and their family
experiences and adjusts to their illness. Such a
comprehensive approach would broaden the perspective on this
disabling disease to include the critical psychosocial
component without sacrificing the enormous advantages of the
biomedical approach (Dakof & Mendelsohn, 1986).
The primary purpose of this study was to determine if
patients with PD would experience decreased impact of
illness and improved psychosocial adjustment to their
illness after treatment with tolcapone. The secondary
purpose of this study was to reveal the clinical
significance of subjective non-disease specific indicators,
quality of life, as critical outcome variables for clinical
practice and research.
This study was done in parallel with a primary double
blind placebo-controlled clinical trial which was conducted
to determine the safety and efficacy of three doses of
tolcapone when compared to patients receiving a placebo
(inactive substance).
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Theoretical Framework
The theoretical framework supporting this study is the
cognitive theory of psychological stress and coping of
Lazarus and Folkman (1984). Coping has long been recognized
as playing a central role in human adaptation. From this
theoretical perspective, coping is the process of managing
demands

(external or internal) that are appraised as taxing

or exceeding the resources of a person. An important
component of this theory is its focus on process and
management rather than mastery of demands facing an
individual. This component is critically important when
studying chronic illnesses such as Parkinsons1s disease
which present patients with lifelong problems that can't be
mastered but can be managed, redefined or tolerated for
optimal adaptation (Folkman & Lazarus, 1984). This
perspective is a necessary one for advanced practice nurses
working in clinical and research practice settings with
chronic illness populations such as Parkinson's Disease.
From this transactional theoretical view, individuals
are in dynamic, mutually reciprocal relationships with their
environment. Such relationships include interactions between
the individual and other individuals and the institutions
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representing his or her sociocultural environment. Such
interactions are usually achieved through loosely prescribed
behavioral patterns termed roles. The functional
efficiencies of an individual's role behaviors (e.g.,
spouse, parent, professional) tend to be highly correlated
with judgments concerning his or her levels of psychosocial
adjustment

(Derogatis & Derogatis, 1990).

Stressful situations which the individual faces, such
as chronic illness, are appraised as either taxing or
exceeding one's resources and therefore posing a threat or
danger to well being. Long term outcomes are moderated by
two processes: cognitive appraisal and coping.
Cognitive appraisal represents an evaluative process of
sources of stress as either harm, threat or challenge. The
appraisal of stressors assists an individual's ability to
produce a positive outcome or, in the case of Parkinson's
Disease, to promote optimal adaptation. Lazarus and Launier
(1978) maintain that the determining feature of response to
a stressor is the individual's appraisal of the situation.
If individuals are able to cope effectively with the
problems they face, they may be able to reduce the harmful
consequences of the stressors (McCrae, 1986) . Coping is
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required to overcome damage or loss, to prevent things from
getting worse, to come to terms with the situation as it is,
or to reinterpret the meaning of the stressor.
In this study, the theory of coping and adaptation of
Lazarus and Folkman was utilized to frame the context of the
role of the impact of Parkinson's Disease, as a harmful
stressor, and psychosocial adjustment before and after a
pharmacological intervention. This theoretical framework
provides the foundation for examining unique outcome
measures, illness impact and psychosocial adjustment, in a
study of a pharmacological intervention. Lazarus and
Launier's perspective of cognitive appraisal of a stressor
(such as Parkinson's Disease) as either harm, threat or
challenge provides support for introduction of the
subjective patient perspective into a traditionally disease
oriented approach. Such a theoretical view brings together
the nursing (person oriented) and medical (disease oriented)
and research perspectives to develop empirical knowledge
necessary to aid patients struggling to manage the stresses
of disabling disease (Lazarus, et al, 1984) .
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Research Hypotheses
The following hypotheses were tested to determine
whether the impact of and adaptation to Parkinson's Disease
is improved after treatment with tolcapone:
1.

Total illness impact will be significantly lower in
individuals with Parkinson's Disease who receive
tolcapone as compared to patients receiving a placebo
(inactive substance).

2.

Physical illness impact will be significantly lower in
individuals with Parkinson's Disease who receive
tolcapone as compared to patients receiving a placebo
(inactive substance).

3.

Psychosocial illness impact will be significantly lower
in individuals with Parkinson's Disease who receive
tolcapone as compared to those receiving a placebo
(inactive substance).

4.

Psychosocial adjustment to illness will be
significantly improved in Parkinson's patients
receiving tolcapone as compared to those receiving a
placebo (inactive substance).
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Definition of Terms
Two major concepts were the focus of this study: impact
of illness, and psychosocial adjustment to illness. The
theoretical definitions of these variables were as follows.
Impact of Illness
The impact of illness is the unique blend of
psychological and somatic sensations imposed by a chronic
illness which upsets or stresses people (Haan, 1982). Impact
of illness was operationalized in this study subjectively by
the Sickness Impact Profile (SIP)

(Bergner 1977) and

objectively by the Unified Parkinson's Disease Rating Scale
(Fahn et Elton, 1987).
Psychosocial Adjustment to Illness
Psychosocial adjustment to illness is the quality of a
patient's psychosocial adjustment to a current medical
illness or its residual effects. Psychosocial adjustment to
illness was operationalized by the Psychosocial Adjustment
to Illness Scale

(PAIS-SR)

(Derogatis & Derogatis, 1983).
Summayy

Chapter I focused on the concepts of impact of illness
and psychosocial adjustment to illness as critical
components in the assessment and treatment of individuals
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with Parkinson's Disease. Traditionally, emphasis has been
placed on an objective disease specific focus. The role and
importance of psychosocial status in overall well being and
quality of life as a critically important variable for
measuring outcome in clinical studies and for determining
clinical improvement has been suggested. The need and
importance of subjective (patient) measurement of
improvement in addition to objective determination of
disease specific measurement has been stressed.
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CHAPTER II
Review Of The Literature
Theoretical discourse on the stress-coping-adjustment
paradigm has been prolific. The existence of the
relationships between the impact of illness (stress),
appraisal of illness and coping has been acknowledged in an
extensive body of literature (Lazarus & Folkman, 1984,
Folkman, Lazarus, Gruen and De Longis, 1986). However, since
the generalizability of the entire paradigm to the patient
with Parkinson's Disease has yet to be confirmed, this study
focused primarily on the illness impact, cognitive
appraisal-adjustment relationship. The impact of a chronic
illness may be even more exaggerated in illnesses which
result in limitations in movement. Limitations in movement
have far reaching consequences which considerably effect
issues of personal independence, role fulfillment, self
esteem and ultimately psychosocial adjustment. Because the
symptoms are very obvious in illnesses effecting movement,
patients often feel stigmatized by their symptoms. Therefore

13
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comparisons with hypertension or heart disease populations
for example do not provide equal comparison groups. The
effect of chronic illness and adjustment in diseases with
limitations in movement, and in Parkinson's Disease in
specific will be addressed.
The Impact of Illness in Diseases Affecting Movement
Illness imposes severe, acute, chronic or recurrent
conditions of psychological stress (Lazarus, 1978). Current
theory and research on the relationship between stressful
events and indicators of adaptational status such as somatic
health and psychological symptoms reflect the belief that
this relationship is mediated by coping processes

(Folkman,

Lazarus, Gruen and De Longis, 1986).
Several approaches have been used to attempt to
identify the mechanisms by which the stress-adaptational
process is mediated. Theoretical approaches have considered
personality characteristics, the characteristics of the
stressful situation itself and generalized coping strategies
applied to all stressful situations.
Though age at diagnosis and disease course varies,
Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS)
samples are often compared to patients with Parkinson's
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Disease because of the similar changes in motoric function,
and the degenerative course of the illness.
Physical health status, personality and interpersonal
functioning of patients with Multiple Sclerosis were studied
by Zeldou and Pavlou (1988) . Illness impact measured by the
Sickness Impact Profile (SIP) was greatest in the physical
domain (m = 24.6) followed by total impact
psychosocial impact

(m = 21.1) and

(m = 17.41). In this study, significant

differences were found between men and women. Thirteen of 18
correlations between physical impact scales and
interpersonal functioning scales were significantly
different for women compared to 0 of 18 correlations in men.
However male subjects reported much greater illness impact
on social interaction (m = 23.20) than females

(m = 14.54, t

= 2.26', p = <. 03) . A significant correlation between age and
physical illness impact was also found (r = .35, p = c.Ol)
and total illness impact

(r = .30, p = <.01) . Differences by

sex in this study suggested further opportunity for inquiry.
The disproportionate sample size of women to men may have
accounted for these findings, however actual differences in
illness impact may exist by gender.
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The role of illness impact, coping responses, and
degree of disability of 20 Multiple Sclerosis (MS) patients
was studied by Buelow (1991). Patients rated fatigue and
uncertainty about the future as most stressful, while
needing help eating or dressing and visual changes were the
least stressful. Degree of disability did not appear to
correlate with stressors (r = .149) . However, a positive
correlation was found between uncertainty about the future
and fatalistic coping style (je = .52, p = c.Ol) and a
negative correlation between depression and optimistic
coping (r= -.155, p = <.01). Cautious interpretation of
these findings must be used however as patients were
hospitalized and possibly felt more secure and less
stressed. In addition, participants were treated with
steroids, often associated with feelings of euphoria which
might have confounded the results.
The possible relationship of two types of stressors,
life events and illness experience, to three sets of
attitudes, life satisfaction, self assessed coping and
satisfaction with treatment was examined in 97 randomly
selected outpatients with multiple sclerosis

(Counte,

Bielauskas, and Pavlou, 1983). Personal life satisfaction
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was measured using the Life Satisfaction Index, and coping
was measured by the MS Adjustment Scales. Life satisfaction
was related to hospitalization,

(f = 11.7, p = c.001), to

anxiety (f = 22.6, p = c.001), to age (f = 3.8, p = <.001),
and to life stress (f = 5.9, p = c.001). Negative
associations of these variables and personal life
satisfaction accounted for 45% of the explained variance.
Higher personal life satisfaction scores were thus found
among patients who were less anxious, younger, those
experiencing fewer stressors and had fewer hospitalizations.
These findings reflected a sample of MS patients with less
disease severity and disease duration which might account
for these findings.
To characterize the impact of rheumatoid arthritis

(RA)

in terms of physical and psychosocial changes, Deyo, Inui,
Leininger and Overman (1982) studied seventy-nine patients
in four functional categories of RA. Participants completed
the Sickness Impact Profile (SIP) to determine the impact of
their disease on physical and psychosocial functioning. When
compared with 624 individuals from a large pre-paid health
plan, RA patients had greater mean illness impact

(Total SIP

scores) 15.6 when compared to health plan member controls
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3.6. The SIP physical and psychosocial dimension scores were
reported to be positively correlated (£ = .478, p = <.001)
in this study. The authors interpreted these correlations to
mean that a t .a given point in time, a decrease in physical
function is accompanied by altered psychosocial status.
However, since these are subscales of the same instrument,
and are calculated together to determine overall illness
impact, correlations would be expected and may not
necessarily be interpreted as concomitant indicators of
physical and psychosocial change indicative of illness at a
given point in time. This criticism would seem to be
appropriate when authors report of the relationship of SIP
scores to functional categories of American Rheumatism
Association (disease severity) was examined. Overall SIP and
Physical Dimension subscale scores increased with increased
disease severity, however, psychosocial dimension scores
increased mildly from class 1 to 2 (less disease severity),
but decreased in class 3 (mild disease severity), while in
class 4 scores (moderate disease severity) psychosocial
function remained the same as it had in class 2 disease
severity. These findings suggested that a linear
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relationship may not have existed between psychosocial
function and increasing disease severity in this sample.
The Impact of Parkinson's Disease
A phenomenologic study of six patients with PD by Marr
(1991) revealed 4 major themes of the illness: a) impact of
disease (also described as loss), b) dealing with the
disease

(social interaction losses), c) maintaining

independence, and d) effort. Though the study sample is
small, it provided qualitative support for the concept of
disease impact in the lives of individuals with PD.
A study to examine the effects of levodopa on activity,
social participation, depression and enjoyment of life was
performed by Singer (1976) soon after the discovery of
levodopa therapy. Singer studied 169 patients, 149 before 9
months treatment with levodopa and 20 who served as
controls. Singer concluded that levodopa therapy did not
reverse but rather conserved the decline in social
functioning, considered a corollary of PD. After treatment
with levodopa, symptom improvement and others expectations,
(p = .246, p = <. 05) , (r; = .217, p = <. 05) were significantly
related to enjoyment of life respectfully. Social
participation was related to symptom improvement,

(r = .224,
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£ = <.05), disease severity,(r = -.308, p = c.Ol), disease
duration (r; = .25, p = c.Ol) and sick role attitudes,

(jr =

.30, ^ = c.Ol) . Overall, only 2 of 15 variables
significantly contributed to post-treatment effect. The
author suggested symptom improvement resulting from
treatment with levodopa appeared to be independent of
patients1 initial level of social and psychological
functioning. Unfortunately this study does not clarify the
specific operationalization of the sociopsychological
variables in terms of measurement, validity, reliability or
evaluative properties. Findings therefore, may not have met
measurement standards for evaluative properties.
Starkstein, Mayberg, Preziosi and Robinson (1992)
studied the relationship of depression, cognitive decline
and impairment in functional ADL in a sample of 105
individuals with PD. Patients were grouped on the basis of
psychiatric evaluation into major, minor or no depression
categories. The patients with major depression showed a
significantly greater cognitive decline (£ = 4.36, p = c.05)
and deterioration in functional ADL (£ = 3.26, p = c.05)
than either the minor or non-depressed group.
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The impact of chronic illness was studied in 145 PD
patients, 735 ET (Essential Tremor) patients and 87 age
matched community controls by Busenbark, Nash, Hubble and
Roller (1991). The SIP was used to compare the impact of
illness related dysfunction in these samples. Patients with
Parkinson's Disease had much higher illness impact scores
(total SIP 19.0) when compared to patients with Essential
Tremor (9.2) and controls (3.4). Similar findings were
reported in both the physical and psychosocial dimension
scores. Psychosocial scores were higher in PD patients
(20.2), when compared to controls (3.6), and in essential
tremor patients (11.7). Physical dimension scores were
similarly highest in PD (17.7), control (2.3), and essential
tremor (9.2). When Parkinson's Disease patients were
compared with essential tremor and controls, total score,
dimension scores and subscale scores were all significantly
different ranging from p = <.0001 to <.05.
In a preliminary study of 12 PD patients and their
spouses, PD patients' impact of illness correlated
significantly (r = .41 p <.01) with duration of illness and
disease stage (r = 0.42, p = <.02) when compared with
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controls who had no significant correlations (Kurlan,
Barold, Page, Como & Shoulson 1989).
Longstreth, Nelson, Linde and Munoz (1992), studied 44
patients with PD and 44 age and sex-matched controls to
determine the utility of the SIP in PD. The SIP (total
score) correlated with the Hoehn and Yahr (r = .59, p =
<.001) and the Columbia Scale (£ = .54, p =.001) .
Significant differences were found between the PD and
control groups on the SIP (16.8, p = c.001), physical
dimension (r = 12.9, p c.005) and psychosocial dimension (r
= 19.4, p = c.001). The authors concluded that the SIP could
be used to supplement PD-specific disability scales to
provide a broad measure of functional status in PD as well
as a promise of documentation of functional changes that
occur with treatment.
In exploring the relationships between aspects of
physical illness (clinical severity, Hoehn and Yahr and
functional disability)

13 6 Parkinsons patients were studied

by MacCarthy and Brown (1989). Self-esteem, coping style and
practical support contributed significantly to the variance
in psychological adjustment. The authors concluded that
well-being in patients with Parkinson's is not exclusively
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dependent on a simple relationship between disability and
depression and that other factors should be taken into
account in the clinical management of the illness.
A controlled trial of piracetam in the treatment of
intellectually impaired patients with Parkinson's Disease
was conducted by Sano, Stern, Marder and Mayeux,

(1990) . The

SIP was used to assess functional status in these patients
and was completed by a family member living with the study
patient. The authors reported a significant improvement in
the SIP (total) score in the piracetam group compared with
the placebo group (p <.05).
The stress of chronic illness in conditions affecting
movement and PD in particular was illustrated by the studies
presented. Patients with PD consistently reported both
physical and psychosocial stress from their illness. Only
the studies of Sano et al.(1990) and Singer (1976) were
evaluative, all other studies were discriminative in nature.
Psychosocial Adjustment to Chronic Illness
Increasing numbers of individuals surviving longer with
chronic illnesses have shifted the focus of interest from
mortality to long term morbidity. The demands made by such
illnesses on the coping skills, psychological integrity, and
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social supports of these patients has brought the
significance of psychosocial adjustment into bold relief
(Derogatis & Derogatis, 1990).
A general model of appraisal, coping and adjustment in
patients with rheumatoid arthritis (RA) was developed by
Smith and Wallston (1992) . Based on the theory of Lazarus
and Folkman, a causal model was used to test the short and
long term adaptation consequences of coping as well as the
antecedent variables
and disease activity)

(appraisals, beliefs, social support,
that promote particular coping styles.

They concluded that interventions designed to bolster a
generalized sense of competence and to discourage
helplessness appraisals and passive coping strategies in
response to pain, have the potential to improve the
psychological adjustment and functional well being of
individuals facing chronic illness.
Cassileth, Lusk, Strouse, Miller, Brown, Cross and
Tenaglia

(1984) studied 758 chronically ill individuals and

concluded that adaptation to chronic illness was independent
of a particular diagnosis. In the six diagnostically
different groups studied no statistically significant
differences in psychological status emerged. However
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patients whose ambulation was affected had lower scores on
the dependent variable Mental Health Index (MHI scores).
Although this study seemed to suggest that diagnostic
category and severity of disease are independent of
adaptation, the populations studied may not have been
comparable when impairment of motor function is more
carefully considered.
Felton, Revenson and Hinricksen (1984) studied 170
patients with diabetes, rheumatoid arthritis, arthritis,
cancer and hypertension. Using a stress-coping model, they
investigated adjustment among the chronically ill using six
different coping strategies. Neither level of disability nor
any other distinction among illnesses played a role in
determining which coping strategies were effective in
promoting adjustment to illness. However, responses to openended questions by patients with cancer and rheumatoid
arthritis suggested that illness related disabilities did
affect psychosocial adjustment. These qualitative findings
suggested that possibly quantitative instruments may not
have been sensitive to disease impact and disability.
Psychosocial adjustment to illness and its relationship
to type and severity of illness, cognitive appraisal
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(meaning of illness) and family function were studied by
Arpin, Fitch, Browne and Corey (1990). In a study of 216
oncology, rheumatology and gastroenterology patients, the
cognitive appraisal or meaning variables exceeded the
importance of all other variables in explaining 14% of a
person's adjustment to illness. While 70% of this sample
reported good adjustment to illness, degree of disability
was positively related to perception of disability
(b = 5.80). These findings may have reflected a sampling
bias in this study in favor of patients with minimal
limitation in physical functioning as only the patients with
oncology diagnoses appeared to have relatively chronic
conditions.
Pollock,

(1986) investigated physiological and

psychological adaptation to chronic illness while
hypothesizing that individuals with a hardiness
characteristic would have more adaptive behavior than
individuals without the characteristic. Studying individuals
with rheumatoid arthritis, diabetes and hypertension,
Pollock found that presence of the hardiness characteristic
was significantly correlated (r = .43) with physiological
adaptation and (r = .62) with psychosocial adaptation in the
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diabetic group but not for the hypertensive or rheumatoid
arthritic groups. Generalizations about chronic illness in
this study could not be made when recognizing that
differences in etiology, symptoms and treatment may present
diverse stressors for patients' adaptive abilities.
Physiological and psychological adaptation to chronic
illness was studied using the Adaptation model in 211
patients

(Pollock, Christian and Sands 1990) . The

personality characteristic of hardiness was the only
variable significantly related to both psychological

(r =

-.13, p = <.05) and physiologic (r = -.16, p = c.Ol)
adaptation. Physiological adaptation was significantly
different among three chronic illness categories

(rheumatoid

arthritis, multiple sclerosis and hypertension). Findings
suggested that physiologic adaptation may be disease
specific and multi-variable comparisons may leave many
questions unanswered.
The influence of physical health status, stressful life
events and various moderator variable on psychosocial
adjustment in a chronically ill (MS) population was studied
by Zeldow and Pavlou (1984). Physical dysfunction as
measured by the SIP had a pervasive influence on personal
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and interpersonal functioning. Mean physical impact scores
were higher (24.6) than psychosocial impact scores (17.4)
and overall impact 21.1 falling in the middle. Using
combined indicators of personality and psychosocial
adjustment, the authors concluded that greater physical
disability is associated with decrements in personal
efficiency and well-being, adaptive autonomy, self-reliance,
social confidence and actual social contacts.
Examination of the relationship of stress appraisal and
coping responses to multiple behavioral indices of illness
adjustment among 101 patients with diverse chronic
conditions was studied by Bombardier, D'Amico and Jordan
(1990) . Variables studied included functional impairment,
depression, symptom severity and coping. Patients indicated
greater psychosocial dysfunction (29.2) than physical impact
(17.6) as rated by the SIP. Using regression analysis,
emotion-focused coping was positively related to poor
psychosocial adjustment

(r = .28) and depression (r = .29)

after controlling for rated disease severity. Appraisal of
illness as limiting one's ability predicted greater emotionfocused coping responses (r = .38) and poorer adjustment to
illness. Use of negative coping strategies predicted
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negative adjustment. Illness stress and functional
impairment were measured by the SIP. The authors concluded
that specific types of illness appraisal and coping
responses were concurrent predictors of illness-related
adaptive functioning, depression and, to a lesser extent
perceived symptom severity.
A longitudinal study of 103 individuals with multiple
sclerosis

(M.S.) looked at self concept measurement

differences

(t2-tl) as an indicator of adjustment to disease

(Brooks and Matson, 1982). No change was found in patient
self concept over time was found during this study. However
when compared to a non-M.S. comparison group, the study
group had a small but significantly different change in self
concept

(t-3.09 (p <.01). In this study, change in mobility

(disease severity) did not correlate significantly with
change in self concept.
A 1994 review of research on psychosocial adjustment to
neuromuscular disorders by Liveenh & Antonak, confirms the
paucity of research in this area specific to individuals
with PD. The authors conclude that numerous clinical and
empirical investigations have studied the occurrence and
nature of depression among people with Parkinson's Disease,
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however little research has been directed at exploring other
psychosocial reactions to this disease (Livneh & Antonak,
1994) .
Patterns of adaptation to PD were studied in 44
patients by Dakof and Mendelshon (1989). Patients
participated in interviews and completed the Symptom
Checklist 90. A Q-sort technique was used to analyze the
interview data. Four clusters of adaptation evolved;
sanguine and engaged (Cluster I), depressed and apprehensive
(Cluster II), depressed, ashamed and misunderstood (Cluster
III) and passive and resigned (Cluster IV). Disease
severity, but not demographic or other health variables,
discriminated the groups. Patients with mild to moderate
impairment adjusted effectively to their illness (Cluster
I ) . Clusters III and IV seemed primarily a function of
physical condition.
Summary
The literature discussed here supports the assumption
that chronic illnesses act as life stressors and that coping
may be a mediator in overall adjustment. The relationship of
disease severity to adjustment and the role of disease
impact as a stressor warrants further study. Studies in

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

movement related diagnoses and in PD in specific revealed a
variety of interpretations of this relationship. Diversity
in the selection of variables and in their
operationalization limits comparison to PD. A majority of
studies provided support for the existence of considerable
psychosocial impact from PD and from other movement related
diseases. The studies reviewed highlight the need and
importance of disease specific reliable and valid
instruments in clinical studies.
The majority of studies were discriminative in nature
rather than evaluative. However, cross-sectional data limits
the applicability of findings especially where degenerative
neurologic diseases are concerned. The need for evaluative
studies is critical to understanding the impact of illness
overtime, the effect of interventions and their relationship
to overall adjustment.
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CHAPTER III
Methodology
Chapter III describes the research design, sample,
instrumentation, data collection and analysis procedures
which were used in this study.
Research Design
This study was done in parallel with a primary double
blind placebo controlled pharmaceutical clinical trial which
was conducted to determine the safety and efficacy of three
doses of tolcapone when compared to placebo (inactive
substance) for the treatment of individuals with Parkinson's
Disease. A nonequivalent control group (naturally assembled,
ambulatory out-patients) design was used for the both
studies

(Campbell & Stanley, 1963). The focus of this

parallel study was to determine if patients participating in
the primary study who were treated with tolcapone
experienced improved psychosocial adjustment to illness and
experienced less impact of illness (PD) than patients
treated with placebo.

32
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Using the criteria detailed by Campbell and Stanley
(1963), the study's design was analyzed for threats to
internal and external validity. Internal validity is the
basic minimum without which any experiment is
uninterpretable: did in fact the experimental treatment make
a difference? In this study all eight threats to internal
validity, history, maturation, testing, instrumentation,
regression, selection, mortality and interation of
selection, maturation etc. were controlled by the
experimental design. The process of random assignment
controlled for the threats to representativeness or
achieving pre-treatment equality of groups. External
validity asks the question of generalizability. Lack of
random selection and the small sample size in this study
limited the generalizability of the findings.
Sample
The target population was composed of individuals
diagnosed with idiopathic Parkinson's Disease being seen at
an outpatient movement disorder clinic. Only individuals who
met the inclusion and exclusion criteria for participation
in the primary study were invited to participate in this
study (see appendix A ) .
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Participants for this study included a sample of 46
individuals with idiopathic Parkinson's Disease who met the
criteria for participation in the primary study. There were
a total of 49 sets of responses (pre and post treatment
questionnaires) with 46 final usable data sets.
The final total study sample was comprised of 19
females (41%) and 27 (59%) males with a mean age of 64
(range 40-79). Of the 46 subjects, 5(12%) were employed and
41 (87%) were retired. The majority or 43 (90%) were
married. A total of 2 (6%) were divorced or separated and 1
(4%) was widowed. Educational level reflected a mean of 13
years of education. Eleven (23%) had high school educations,
18 (34%) had graduated from college and 10 (21%) had
received graduate or professional education. The mean
duration of PD was 10.25 years (range of 2.3 to 20.3) .
Random assignment to treatment groups was determined
and conducted prior to the first patient enrollment by the
sponsor of the primary study. Dose-related treatment groups
were utilized to meet sampling needs for the primary study.
Homogeneity across groups was confirmed prior to data
analyses and is discussed in Chapter 4. Demographic
characteristics of the subjects by treatment group are
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illustrated in Table 1. Under blinded conditions, ten
patients each were assigned to the 50 and 400mg groups, 12
to the 200mg group and 14 to the placebo group. Age across
treatment groups ranged from a low of 62 in the placebo
group to a high of 67 in the 400mg group. Duration of PD was
lowest in the placebo group, 8 years, to a high of 12 in the
50mg group. Unified Parkinson's Disease Rating Scale (UPDRS)
score for motor function ranged from a low of 32 in the
400mg group to a high of 39 in the 50mg group. A total UPDRS
score low of 37 was noted in the 400mg group to a high of 47
in the placebo group. Disease staging as measured by the
Hoehn/Yahr was the same, 2, across all treatment groups.
Projective statistical techniques were used to
determine what size samples would be needed to detect the
same changes as were found in this study. These calculations
suggested that if all participants in the multi-center study
(n = 152) had participated in this study, significant
differences at the p = .05 level might have been detected.
Despite the advantages provided by the experimental
design, the findings of this study are limited because of
the small sample size. The samples for each treatment group
did not reach those projected by the a-priori power analysis
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Table 1
Sample Description by Treatment Group

Characteristic- Placebo

Tolocapone
200mg
50mg

400mg

n

14

10

12

10

Age

62

64

64

67

8

12

9

11

Motor UPDRS*

38

39

35

32

Total UPDRS*

47

46

45

37

2

2

2

2

PD

Duration

Hoehn/Yahr*

*Disease severity determinant
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calculations. This limits the findings from three
perspectives: a) small treatment group sizes minimize the
possibility for detection of significant differences between
groups and b) limits the generalizability of the study's
overall findings and c) the possibility of variability in
such small cell sizes could obscure any real differences
between groups.
Instrumentation
The following sections describe the instruments used in
the study. Representative items from each data collection
instrument are presented in the Appendices.
Sickness Impact Profile (SIP)
The Sickness Impact Profile (see Appendix B) is
composed of 136 items describing specific health related
dysfunction behaviors. Respondents check only items
describing dysfunction due to their illness. The purpose of
the instrument is to provide a behaviorally-based measure of
health status or illness impact (Bergner, 1977). The SIP
results reflect a subject's perception of performance of
those activities associated with daily life activities. The
instrument is composed of two dimensions, physical
subscales)

and psychosocial

(3

(4 subscales), and five
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independent categories for a total of 12 subscales. In this
study the SIP results were computed using an overall
total illness impact score,

(the sum of all subscales), a

physical dimension score (the sum of the ambulation,
mobility and body care and movement subscales), a
psychosocial dimension score (the sum of the emotional
behavior, social interaction, alertness and communication
subscales), and 5 individual independent category scores
(the work, sleep and rest, eating, home management and
recreation and pastimes subscales).
The SIP has been tested extensively in many diagnostic
categories for test-rest reliability (x = 0.92) and internal
consistency reliability (x = 0.94). Results are well above
the .80 acceptable limit for interviewer-administered and
self-administered instruments

(Nunnally, 1978). Convergent

and discriminant validity have been evaluated using the
multi-trait multi-method techniques. A summary of the
multitrait-multimethod correlations of overall scores of the
SIP with the SAD (self-assessment of dysfunction), SAS (self
assessment of sickness), and the NHIS (National Health
Interview Survey Index of Activity Limitation) were 0.92,
0.82, 0.86 and 0.85 respectively (Bergner, 1981).
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A cross sectional study by Longstreth et al.

(1992) was

performed to determine the utility of the SIP with PD
patients. The overall SIP score, the physical dimension and
psychosocial dimensions were significantly correlated (p
<.001) with the gold standard PD disability measures

(Hoehn

and Yahr [see Appendix E] and the Columbia Scale).
In this study the SIP Cronbach's alpha coefficient was
0.89 for the entire instrument. Subscale alpha's ranged from
0.86 to 0.87. Prior to the experimental, intervention the
SIP total score correlated with the disability measures
(baseline motor UPDRS score),

(x = .45, p = .001), and with

the total UPDRS (r = .55, p = .0001). The SIP also was
correlated with the Hoehn and Yahr (r = .42, p = .003) .
These findings were similar to Longstreth1s (1992)
suggesting a relationship between motor function and disease
severity.
Psychosocial Adjustment to Illness-SR (PAIS-SR)
The PAIS-SR (see appendix C) is a self report
instrument designed to assess the quality of a patient's
psychosocial adjustment to a current medical illness
(Derogatis, 1978). This 46 item Likert type instrument has
been used extensively in psychological, sociological and
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clinical medical settings (Derogatis,1990). The seven
subscales of the PAIS-SR were developed through a
combination of rational-deductive and empirical-analytic
techniques. Internal consistency testing of the PAIS-SR was
assessed in three chronic illness populations: dialysis,
lung cancer and cardiac patients. Cronbach's alpha
coefficients for the dialysis population ranged from 0.630.80, in the cancer patients the range was from 0.12-0.93
and in the cardiac population from 0.47 to 0.85. The
subscale which included the item with the .12 score has been
revised.
Construct validation and principal components analysis
provided support for the seven theorized dimensions using a
cancer cohort of 120 patients. The PAIS-SR was tested for
convergent validity in comparison with four like measures of
psychological distress: the Affect Balance Scale

(ABS), SCL-

90-R General Severity Index, and the Patient's Attitudes,
Information and Expectancies Scale (PAIE). PAIS-SR total
score correlated with the GAIS (x = .81), SCL-90

(r. = .60),

ABS (r = .69) and PAIE (£ = .64).
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Internal consistency estimations for the PAIS-SR in
this study were 0.80 for the total instrument with subscale
alphas ranging from 0.75 to 0.81.
Unified Parkinson's Disease Rating Scale (UPDRS)
The UPDRS

(see Appendix D) is a clinical evaluation

method commonly used by movement disorder specialists to
objectively assess an individuals symptoms of Parkinson's
Disease

(Fahn & Elton, 1987). The instrument contains three

dimensions: 1) mood, 2) ADL (activities of daily living),
and 3) motor. In this study the motor UPDRS scores were
used. The motor score reported is in the "off" condition.
This score was determined by physical examination on day 1
(prior to) and on day 42, at the conclusion of treatment
with tolcapone

(endpoint). The "off" condition is defined as

motor function without the benefit of levodopa treatment and
is considered the best approximation of improvement over
time. Sample items from the UPDRS appear in Appendix B.
Reliability and validity were not published at the time of
development, however a post hoc assessment was performed by
van Hilten, van der Zwan, Zwinderman and Roos, 1994.
Reliability estimates of 0.88 for the total score and
concurrent validity of r = 0.75 when compared with the Hoehn
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and Yahr were reported (van Hilten, van der Zwan,
Zwindermkan and Roos, 1994). The UPDRS is considered the
"gold standard" by movement disorder specialist for
determining motor function in individuals with PD in
clinical and research settings.
Hoehn and Yahr
The Hoehn and Yahr (see Appendix E) is a 5 point scale
used to categorize a patient's disease stage. Hoehn and Yahr
data were collected in order to analyze subgroup differences
by disease stage and to determine if patients disease stage
was acceptable for initial eligibility for the primary
study.
Demographic Questionnaire
An investigator-developed demographic questionnaire was
used to collect representative demographic data (see
Appendix F ) . These data were used to describe the sample as
well as to allow for analysis of specific subsets within the
sample and potential correlations with outcome variables.
Representative demographic data included age, sex,
education, marital status, and number of years with PD.
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Data Collection
Approval to conduct the research was obtained from the
Research Committee at the University-affiliated movement
disorder clinic where patients were recruited, and from the
Committee for the Protection of Human Subjects (CPHS) at the
University of San Diego (see Appendix G ) . After permission
was obtained from the appropriate institutions, chart
abstraction was used to gather information to determine
preliminary subject eligibility. Patients meeting the
criteria for inclusion were approached to determine their
interest in participation (see Appendix A ) . Individuals
received a complete explanation of the project including
assurance of confidentiality and anonymity. Individuals who
agreed to participate, provided informed consent and who met
the inclusion and exclusion criteria were scheduled for a
preliminary screening visit.
Qualified and consenting subjects came to the clinic
for disease severity determination and rating of motor
symptoms by a physician specially trained in movement
disorders. Patients who met the primary study inclusion
criteria and who provided informed consent were approached
for participation in the nursing study. At the screening
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visit for the primary study, all participants had a complete
physical and neurologic exam, safety laboratory tests, an
EKG, and urinalysis. Participants were also instructed in
how to complete a diary of their Parkinson symptoms.
Participants whose screening exams were normal returned in 2
weeks for a baseline visit for the primary study. At the
baseline visit, all nursing study participants completed the
nursing study instrument packet, prior to beginning
treatment with the investigational medication. Participants
began treatment on the day following the baseline visit with
one of the three double blind doses of study medication or
placebo. Participant experimental group assignment had been
pre-randomized by the primary study sponsor. Study
participants were followed over six required primary study
visits for safety and monitoring purposes. On the final
visit of the primary study, day 42, all nursing study
participants completed a second set of nursing study
instruments identical to those completed at the baseline
visit.
Data Analysis
Descriptive statistics were used to characterize the
sample and distribution characteristics. Measures of
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variability were calculated on the control and treatment
groups to determine the homogeneity of the treatment groups
in order to meet statistical test assumptions. Nonparametric statistical techniques were used for comparison
of subgroup distributions within the sample because of the
nominal level of the data (Kerlinger, 1989) .
Pearson's Product Moment Correlation coefficients were
calculated to determine relationships between demographic
and study variables.
The research hypotheses were tested using repeated
measures analysis of variance and planned comparisons
(Munro, Visantainer & Page, 198 6). Assumption requirements
of homogeneity of variance, equality of covariance matrices
and compound symmetry were satisfied prior to analyses.
Following preliminary hypothesis testing, further post-hoc
analysis were performed where indicated.
The statistical tests were selected based on the
assumptions of homogeneity of variance

(the groups should

have equal variances), mutual exclusivity (the groups are
independent of each other) and compound symmetry. There are
two components of compound symmetry; the correlations across
the measurements are the same, and that the variances should
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be equal across measurements (Munro et al., 1986). The
assumptions of the repeated measures analysis of variance
were all met prior to the analyses.
Summary
This chapter has detailed the methods used in the
study. An experimental design was used to test the
hypotheses in this study. It was hypothesized that impact of
illness and psychosocial adjustment would improve after
treatment with tolcapone. A naturally existing sample of
individuals with idiopathic Parkinson's Disease were
randomly assigned to one of four treatment conditions of a
double-blind placebo controlled primary study of tolcapone.
Repeated measures analysis of variance was used to test
hypotheses posed for this study. Post-hoc analysis was also
performed to insure treatment group homogeneity.
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CHAPTER IV
RESULTS
Study findings are presented in this chapter. The
chapter includes the following sections: 1) data reduction,
2) determination of homogeneity of treatment groups, 3)
hypothesis testing, and 4) post-hoc analyses.
Data Reduction
Data reduction was accomplished through a plan of data
cleaning. Prior to data entry procedures, all study
instruments were scrutinized for missing data and
unacceptable data which were defined as data out of range of
study variable limits. Initially 49 sets or partial sets
(pre and post questionnaires) were considered for inclusion.
Following extensive cleaning and data verification, 46
complete sets of data were used for analysis with the SIP,
PAIS-SR, demographic data and functional status
measurements.

47
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Determination of Homogeneity of Treatment Groups
Homogeneity of treatment groups was determined using
analysis of variance procedures on all demographic and
treatment variables. In this double blind design, all
subjects received treatment

(placebo included), therefore

all groups were included in analyses. No significant
differences were found between demographic or treatment
variables when comparisons by treatment group were examined.
Post-hoc analyses using Scheffe's test and Bonferroni

(Dunn)

T tests confirmed that no significant differences existed
between members of any of the treatment groups

(Munro,

Visantainter & Page, 1986).
Hypotheses Testing
Repeated measures analysis of variance planned
comparisons were performed to test the study hypotheses.
Tests of the assumptions of multivariate normality, equality
of covariance and compound symmetry were met for each of the
hypotheses prior to performing the analyses

(Munro et a l .,

1986). Table 2 summarizes the results of hypotheses testing.
Using repeated measures analyses, significant differences
were detected when combined dose-related treatment groups
were compared to the placebo group for each of the three
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Table 2
Results of Hypotheses Testincr

SS

DF

MS

F

P

Illness Impact

303.138
1207.071

1
42

303.138
30 .240

10.024

< .003

Physical Impact

246.279
943.922

1
42

246 .279
22 .474

10.958

< .002

349.042
1792.042

1
42

349.042
42.684

8.177

<.007

9758.970
173972.828

1
42

9758.970
4142.210

2.356

<.132

Psychosocial
Impact
Adjustment
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illness impact hypotheses. These groups were conbined due to
the small number of subjects per group, and to specifically
test the hypotheses generated for the study.
Hypothesis 1 . Patients receiving tolcapone experienced
significantly less total illness impact (p. = <.003) when
compared to patients receiving placebo.
Hypothesis 2 . Patients receiving tolcapone experienced
significantly less physical illness impact

(p = <.002) when

compared to patients receiving placebo.
Hypothesis 3 . Patients receiving tolcapone experienced
significantly less psychosocial illness impact (p= <.007)
when compared to patients receiving placebo.
Hypothesis 4 . Psychosocial adjustment to illness was
improved in all patients after treatment with tolcapone but
did not differ significantly from patients receiving a
placebo.
Post-Hoc Analyses
Individual variable score change from baseline to week
six (day 42) was used to compute the differences in SIP and
PAIS-SR scores for subjects in the placebo group and
treatment groups.
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Post-hoc analyses were performed to determine if any
significant pairwise comparisons of individual treatment
groups could be found. When the changes in scores from
baseline to endpoint were compared no significant
differences were found. However, when the percent change was
tested using a Bonferroi (Dunn) T, a significant

(p = <.05)

change from baseline to endpoint was found between the 200mg
tolcapone and placebo groups.
Though the changes in illness impact and psychosocial
adjustment from baseline to endpoint were not statistically
different by individual treatment group, the importance in
the changes noted may be more clinically than statistically
relevant. Figures 1, 2, and 3 illustrate the changes found
in illness impact. The importance of clinical significance
is discussed in Chapter 5.
Reductions in illness impact were found in all three
tolcapone dose treatment groups in total illness impact
(SIP) scores, physical dimension scores and psychosocial
dimension scores. In contrast, patients in the placebo group
reported increases (worsening) in illness impact over the
same 6 week period. Table 3 illiistrates the pre- to post
scores . Though none of these changes were found to be
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Total Illness Impact After Treatment with Tolcapone
Change scores from baseline to day 42

20-1

181614-

O PLACEBO
♦ 50 MG

12 -

■ 200 MG
• 400 MG

10

Pre-Treatment

Figure 1 :

Post-Treatment

Total Illness Impact After Treatment with

Tolcapone
U l

to
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Physical Illness Impact After Treatment with Tolcapone
Change scores from baseline lo day 42

16-i
14-

12 -

10
8

O PLACEBO
-

♦ 50 MG
■ 200 MG
• 400 MG

-

6-J.

Pre-Treatment

Figure 2 ;
Tolcapone

Post-Treatment

Physical Illness Impact After Treatment with
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Psychosocial Illness Impact After Treatment with Tolcapone
Change scores from baseline to day 42
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Table 3
Dose Related Illness Impact Pre/Post Treatment

Placebo
14

n

Tolcapone
200mg
400mg

50mg

12

10

10

Pre

Post

Pre

Post

Pre

Post

Pre

Post

Tot a l SIP

16.8

18.0

17.0

13 .7

19.1

14 .6

15.9

10.2

Physical

11.6

13 .2

15.0

9.7

15.1

13.5

10.8

6.1

P sycho s o c i a l

17.5

18.7

14.9

12.4

18.0

11.4

16.0

10 .7

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

56
statistically significant by treatment group, all of the
treatment groups reported they experienced less clinical
illness impact. Similarly in all of the tolcapone treatment
groups, the 12 individual category scores of illness impact
(total scores) patients reported improvement (lowering of
illness impact scores) in all categories with the exception
of 2. In the 50mg tolcapone group no change was reported
(0.0) between baseline and 6 weeks. Similarly, the 200mg
tolcapone group reported a 2.2 change (worsening) in
mobility from baseline to week 6.
In the placebo group 8 category scores increased
(worsening of illness impact) while 3 reported improving and
1 score with no change (0.0) . Patients receiving placebo
reported a (-0.2) change in emotional behavior, a (-5.2)
change in communication, and a (-6.8) change in recreation.
The raw change and percent change scores are illustrated in
Table 4.
Similarly, though no significant differences were found
in psychosocial adjustment to illness, many dose related
response improvements were observed in a subscale analyses
of the PAIS-SR. In the total sample post-treatment
improvement was found in a majority of the subscales and in
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Table 4
Illness Impact Change From Baseline to Endpoint

Placebo

50mg

200mg

40 0mg

Score Change
Raw (%)
Illness Impact

+1.2 (7%)

-3.3 (20%)

-4.5 (23%)

-5.7 (36%)

Physical

+1.5(13%)

-5.4 (36%)

-1.6(11%)

-4.6 (43%)

Psychosocial

+1.2 (7%)

-2 .6 (17%)

-6.6(37%)

-5.4 (34%)

-16(5%)

-12(3%)

-20 (6%)

-1.1(2%)

-3.5 (8%)

-3.2 (8%)

Adjustment
UPDRS motor

- .6 (<1%)
+0.8(2%)
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the PAIS-SR total score (Table 5). In the 200mg Tolcapone
group, all subscale and total scores were improved. In the
50mg and 4 00mg groups, small negative changes (+.1 and +.2)
were found respectfully in the extended family relationship
subscale. The 50mg group also reported a (+.5) worsening in
psychological distress. In contrast the placebo group
reported psychosocial adjustment worsened in the sexual
relationship (+1.28) and social environment

(+.61)

subscales. However, placebo patients reported improvement in
orientation to healthcare environment
environment

(-.43), vocational

(-.57), domestic environment

(-.93) and extended

family relationships (-.14). Total PAIS-SR scores improved
by (-.64). Though many of the improvements in illness impact
and psychosocial adjustment were not statistically
significant, the importance of these findings appeared to be
in the realm of clinical significance.
At baseline, indicators of association were found
between the impact of illness (SIP) and disease severtiy.
Similar correlations were not found between the PAIS-SR and
disease severity. Table 6 describes the associations found
at baseline and correlations of change found at endpoint.
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Table 5
Dose Related Psychosocial Adjustment Responses

n

Placebo
14

50mg
10

200mg
12

400mg
10

Pre

Post

Pre

Post

Pre

Post

Pre

Post

HCSUB

6.0

-5.6

4.9

3.7

7.0

6.1

5.1

3.4

VESUB

6.4

-5.1

7.4

6.2

5.6

2.9

5.5

5.2

DESUB

7.6

-6.7

7.2

5.3

7.9

7.3

4 .9

4.5

FRSUB

2.4

-2.5

1.2

1.3

3.0

2.4

.9

1.1

SRSUB

4.3

5.0

3.1

3.1

5.8

5.1

5.4

5.1

SESUB

6.9

7.5

7.6

6.2

6.8

6.5

5.3

3 .8

PDSUB

5.3

5.7

6.4

6.9

6.0

4.6

8.0

5.9

RAW

357

356

354

337

364

352

345

325

HCSUB-Healthcare orientation VESUB-Vocational Environment
D E S U B - D o m e s t i c e nvironment F R S U B - E x t e n d e d F a m i l y R e l a t i o n s h i p
S R S U B - S e x u a l Re l a i t o n s h i p s SES U B - S o c i a l E n v i r o n m e n t
P D S U B - P s y c h o l o g i c a l D i s t r e s s RAW- Total A d j u s t m e n t Score
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Table 6
Post Hoc Comparison

UPDRS Total

Motor UPDRS

Hoehn

& Yahr
Pre

Post

Pre

Post

Pre

Post

SIP TOTAL

.55***
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At endpoint, minimal correlations of change were found
between disease severity and illness impact

(£ = .25, p =

< .08), and SIP psychosocial dimension (£ = .26, p = <.08)
suggesting the relationship between disease severity and
illness impact may have been independent of the treatment.
Summary
This chapter has summarized the methods used to
accomplish data reduction and confirm homogeneity of
treatment groups. Correlations between demographic and study
variables and hypotheses testing and results were discussed.
The impact of illness was lessened in individuals treated
with tolcapone. When compared with improvement in motor
function, illness impact percent change appeared to be more
responsive to treatment. Psychosocial adjustment though
improved in individuals treated with tolcapone appeared to
be a less robust response than illness impact.
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CHAPTER V
DISCUSSION AND RECOMMENDATIONS
This chapter presents a discussion of the findings of
the study, the strengths and limitations of the study, and
recommendations for future research. The study's findings
are compared and contrasted to previous research reported in
the literature.
Illness Impact
The patient's perspective of the impact of Parkinson's
Disease on overall quality of life has been a major focus of
this study. Illness impact emerged as the most robust
variable. Pre to post treatment changes in total i i ^ e s s
impact, physical impact and psychosocial impact scores
primarily followed a treatment response pattern (placebo
patients worsened, and treatment patients improved) over the
length of the study.
Baseline illness impact scores for toter ;j^a.ct,
physical impact and psychosocial .impq.^’’ ••^“■e (17.29).
(13.10) and (16.78) respect fariv* - These werA somewhat
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different from those of Busenbark et al.'s (1991)study of PD
patients. Busenbark's

(1991) sample appeared to experience

more illness impact than this sample with total scores of
(19.0), physical dimension scores of (17.1), and
psychosocial dimension scores of (20.2). In contrast, Zeldow
and Pavlou's
scores,

(1988) MS sample had higher physical impact

(22.3)lower psychosocial impact scores,

more similar in total impact
study sample. Deyo et al.'s

(14.0) and

(19.2) when compared to this
(1982) study of Rheumatoid

Arthritis (RA) patients rated total impact (15.6), physical
impact

(14.0) and psychosocial impact (11.3) indicating the

RA patients felt less illness impact than the PD patients in
this study.
Sano et al.

(1990), in a study of PD dementia, reported

the only evaluative use of the variable of illness impact in
a movement disorder related sample. They reported
significantly (p <.05) more subjects categorized as improved
on the SIP score in the treatment group compared to the
placebo group however no actual data for this conclusion was
published (Sano et al.,1990). Significant improvement was
reported in the drug treatment group compared to the placebo
group on the rating of recreation and pastime. Again no

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

64
actual data were published. The present study's findings had
similarities to those reported by Sano, et al.

(1990). Total

illness impact improved across all treatment groups when
compared to the placebo, as did the recreation and pastime
subscale scores in the three treatment arms. However, in
this study, the recreation and pastime subscale in the
placebo group actually reported improvement by (+ 6.75) .
Such a change can only be accounted for by a "placebo"
effect since all of the other placebo group scores increased
(worsened) during the study, with the exception of very
small changes in the emotional behavior subscale (10.66 pre,
10.46 post) and work subscale (43.16 pre and 43.13 post).
Comparisons with Sano et al.'s (1990) study must be done
with caution. Raw data were not reported and therefore
actual comparisons of methods/analysis could not be done
with precision.
When comparing the published SIP scores of related
samples, and of studies with PD patients, the PD sample in
this study appeared to be consistent with existing
literature with respect to the variability in disease
severity among individuals with PD. The motor scores of
patients in this study were compared on the basis of the
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worst "off" of the day (approximately 8-10 hours without
medication). All patients were evaluated under the same
conditions in order to control for between patient
variability. This element of control is not usually found in
cross-sectional studies and therefore provides a higher
level of precision of measurement.
Disease Severity and Illness Impact
The relationship between disease severity and illness
impact was explored using bivariate correlations. Ratings of
disease severity at baseline (UPDRS total and motor and
Hoehn and Yahr) indicated that all three measures were
associated with many components of illness impact. Since
Parkinson's Disease is progressive in nature, disease
staging indicators

(Hoehn and Yahr) could be expected to be

associated with indicators of illness stress. This study's
findings like those of Zeldow & Pavlou (1988) revealed that
severity of illness (not duration) was a more influential
determinant of a patients perception of impact of illness.
Duration of PD was only mildly correlated with emotional
behavior and home management.
The findings of this study were similar to those of
Brown and MacCarthy's study of PD who found significant
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associations of illness stress and patient self report of
best/worst disease severity (£ = .54, p = <.001, s. = .52, p
= <.001) .
In contrast, in Kurlan et al.'s study (1989) the SIP
total correlated significantly (r = .32, p <0.5) with age
and more closely with duration of PD (r = .41 p = <.01) and
Hoehn/Yahr (r = 0.42, p = <0.2). Comparable findings in this
study support Kurlans1 data on the relationship of disease
severity and the SIP total (motor UPDRS and Hoehn/Yahr both
significantly correlated (p = <.001 and p = <.003)
respectfully. However they differ in that age did not
correlate with illness impact in this study as it did in
Kurlan, et al.'s

(1989) study.

Busenbark, et al.'s (1991) study published no data of
correlations of SIP with disease severity, however they did
report that PD patients scored significantly higher than ET
patients in total SIP, physical dimension and psychosocial
dimension scores.
In this study, the change in motor UPDRS (from baseline
to endpoint) was only mildly correlated with the change in
SIP total (r = .26, p = <.09) and the change in SIP
psychosocial score (£ =.26, p = <.08) . These findings
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suggested that although motor function was improved by
treatment with tolcapone, the changes in illness impact
appeared to be independent of changes in motor function.
Psychosocial Adjustment and Disease Severity
At baseline, disease severity was not as strongly
associated with psychosocial adjustment as was impact of
illness. Motor UPDRS was associated with only 2 PAIS
subscales, domestic environment

(r = 25, p = <.09) and

sexual relationships (x = -43, p = <.003). Total UPDRS was
associated with the same subscales domestic environment
.33, p = 0.02) and sexual relationships

(x =

(x = .45, p =

<.002) . In addition there was also an association with
social environment (x = -30, p = <.04). The psychological
distress subscale and PAIS-SR total score were related to
duration of PD, motor UPDRS at baseline, total UPDRS at
baseline and Hoehn/Yahr. Duration of PD at baseline was not
correlated with any of the subscale or total PAIS-SR
measures. These findings are similar to those of MacCarthy
and Brown,

(1989) whose adjustment measure of depression was

associated with disease severity (x = .37, p = <.001 and
acceptance of illness (x= -55, p = <.001). Functional
disability (as measured by ADL) proved to be the index which
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best predicted depression in MacCarthy's study of PD
patient's .
These findings supported those of previous studies
(MacCarthy & Brown, 1989, Viney & Westbrook, 1984) which
suggested that adjustment to chronic illness may be more
closely related to appraisal of illness and intervening
variables than disease severity or duration alone. Larger
evaluative studies of PD such as this one, would aid in
clarifying these preliminary findings.
Illness Impact and Psychosocial Adjustment
The impact of illness as a stressor in Parkinson's
Disease has been supported by this study's findings.
All three hypotheses of the effect of tolcapone on
decreasing illness impact were supported. The relationship
of decreased illness impact as a contributor to psychosocial
adjustment remains unclear. The relationship of change in
illness impact and change in psychosocial adjustment is also
unclear. The significant change over time of selected
illness impact variables and their association with
adjustment suggests the need for future studies with larger
samples sizes and similar control measures. Change in
psychosocial adjustment was associated with change in SIP
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total score (r = .25, p = <.ll). This nonsignificant
association only mildly supports the relationship found at
baseline

(p = .72, p = <.0001). Further studies are needed

to fully understand the nature of this relationship.
Clinical Significance
Previous evaluative studies in PD have primarily
focused on physiologic or disease state outcome measures.
The importance of these studies rests more on clinical
significance. Physiologic or disease state measurement
provides information to clinicians but are of limited
interest to patients and may often correlate poorly with
functional capactiy or perceived well being (Guyatt, Feeny,
& Patrick, 1993). The key to clinical significance lies in
interpretability, whether a particular change in score
represents a trivial, small but important, moderate or large
improvement, or deterioration.
In this study, changes in illness impact and disease
state were standardized into percent change scores in order
to enhance interpretability. Using statistical techniques
(t-tests) only 1 of 20 pairwise comparison's were
significant

(total illness impact in the 400mg group

compared to placebo). However, using the standardized
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percent change comparisons, nine of nine illness impact by
treatment group comparisons showed improvment (11% to 43%).
In comparison the traditional disease severity percent
changes showed improvement however considerably smaller than
the quality of life variables (2% to 8%). Such differences
suggested that traditional disease severity assessments,
however informative for treatment considerations, may not
correlate well with patients perception of functional
capacity or well being.
Implications and Recommendations
The importance of subjective patient centered
measurement of disease symptoms and experience has yet to be
recognized in all areas of neuroscience practice. Findings
from studies such as this highlight the need for
incorporation of this critical component into clinical
practice.
The evaluative methods used in this study provide a new
level of knowledge compared to previous cross sectional
studies. Interpretation and application of findings must be
cautious, however, because of the small sample size. However
power analysis estimation using the treatment differences
found in this study, project that significant differences at
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the .05 and .03 levels could be detected if this study were
replicated with larger sample size studies. Despite the
importance of generalizability of findings, it should not be
overlooked that, when examining differences in clinical
status and function, the importance of small if not
significant changes should be considered.
In the out patient setting, improvement and change is
often measured objectively, by the clinician. Determination
of improvement may be based not on significant benefit from
therapy, but by lack of adverse effects or deterioration
from a previous assessment. Previous studies have examined
disease state alone without inclusion of subjective or
quality of life outcome measures. The importance of
subjective outcome measures is particularly important when
considering outcome in the geriatric age group such as
Parkinson's disease. Elderly patients often suffer from
ongoing disabilities which confound their illness
experience.
It is obvious that quality of life can be significantly
affected by PD and the drugs employed to treat it (Roller,
1994). A concern has been raised that these (quality of
life) instruments may not have the sensitivity to detect
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changes in quality of life compared with the more
traditional measures of clinical status (Koller, 1994). Two
important points should be raised: quality of life measures
may include functional (disease status) components, but are
not limited to this focus. Psychometrically sound, disease
specific QOL instruments may prove to be equally sensitive
to traditional measures considering the subjective nature of
their source. The disabilities resulting from PD are not
limited to manifestations of motor function alone. Sleep
disturbances, sexual dysfunction, mental status changes are
but a few examples of disability which may be related to the
disease or from drug therapy and are overlooked in
traditional disease focused measurements.
The findings of this study support just such a
possibility. In the case of illness impact, 9 of 9 variables
had greater percent change improvement than the "gold
standard" UPDRS. Illness impact change (improvement) after
treatment with tolcapone ranged from 11% improvement to 43%
improvement, compared with 2% to 8% improvement in motor
UPDRS score. In the case of psychosocial adjustment,
improvement ranged from 0% to 33% (see Table 4). Such
changes highlight the importance of measurement of quality
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of life in evaluative studies of PD. Clearly these findings
suggest that patients perceive the impact of their illness
in many areas besides motoric function.
The importance of utilizing research findings as a
basis for future studies is critical. This study illustrates
the importance of evaluative clinical studies which include
prior research findings in addition to traditional measures.
Maintaining a narrowly focused view on disease
symptomatology and indicators, forgoes the rich
possibilities of utilizing subject based studies.
One of the most important implications of this study is
recognition of the necessity of including quality of life
assessment into routine clinical practice. As the shift of
health care delivery moves into the out-patient and home
setting, nurses will be called upon to assist patients and
their families to adapt to the stressors of chronic illness.
Though this study has utilized formal research measurement
techniques, these same instruments may be used in clinical
practice situations as assessment techniques at intake, for
follow-up over time, or for determining change or
improvement with treatment. Determining change in functional
status in chronic illness situations often presents the
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clinician with a challenge in trying to quantify change. Use
of quality of life measurement will augment assessment with
additional and enriched data for determining a plan of care.
Summary
Using repeated measures analysis of variance
techniques, this study provided new information on the
impact of chronic illness and its1 treatment in adjustment
to Parkinson's Disease. In addition, it sheds light on the
role and relationship of pharmacological treatment in
quality of life for patients with Parkinson's Disease.
Health care outcomes will increasingly be measured from
the patients point of view. Benefits of treatments and the
overall health care system will be judged in terms of the
extent to which changes in the patient's functioning or well
being meet his/her needs and expectations (Ware, 1992).
The shift in health care delivery, and the focus on the
patient rather than disease systems will bring nursing into
new partnerships in health care delivery. Focusing on the
patient

(as a whole entity) is not a new revelation to

nursing practice. However, the moment must be seized.
Increasing routine nursing assessments to include a broader
functional status component will allow for evaluation in
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terms of impact on patient functioning and well being in
addition to traditionally defined endpoints.
Assisting patients and their families to live
successfully, to adapt and cope with the long term effects
of chronic illness such as Parkinson's Disease will be a
challenge of the future. Nursing has the opportunity to
contribute to the delivery of outpatient care, by utilizing
research findings such as these to improve the overall
quality of patient's lives.
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APPENDIX A
INCLUSION/EXCLUSION CRITERIA OF DOUBLE-BLIND STUDY
Inclusion Criteria:
1.

Onset of PD at age 3 0 or older.

2.

Male or female (surgically sterile or amenorrheic for
one year).

3.

Patients with predictable ON response to the first
daily dose of Sinemet.

4.

Patients taking three doses of Sinemet/day, 1:4 ratio,
stable for at least one month, with four off periods
not including the first off on arising.

5.

Patients must be able to complete diaries recording,
on, off medication times and demonstrating four or more
off periods in 10 hours.

6.

Patient must be compliant at least 90% during the
placebo baseline period.

7.

Patients must sign a written informed consent.

Exclusion Criteria:
1.

Patients with

atypical Parkinsonian variations.

2.

Patients with

unpredictable motor fluctuations.

3.

Patients with

a history of cerebral insult sufficient

to cause delayed secondary Parkinsonism.
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4.

Patients with drug-induced Parkinsonism.

5.

Patients with a Hoehn and Yahr stage 4 Or 5 when ON.

6.

Patients with resting tremor as the sole manifestation
of Parkinson's Disease.

7.

Patients with dyskinesias that are severely or
completely disabling.

8.

Patients with clinically significant hepatic, renal,
cardiovascular, endocrinologic, respiratory, neurologic
or gastrointestinal disorders, or other current medical
problems that may place them at increased risk. This
includes people with clinically significant laboratory,
vital sign or ECG abnormalities.

9.

Patients with psychotic illnesses, chronic psychiatric
disorders, drug or alcohol dependence.

10.

Patients with intellectual impairment as determined by
a score of 25 or less on the Mini-Mental status.

11.

Patients treated within the preceding six months with
dopamine antagonists.

12.

Patients treated within the preceding two months with a
MAO inhibitor.
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13.

Patients treatment within the preceding one month with
peripheral dopamine antagonists or any investigational
drug.

14.

Patients treated within the preceding one month with
psychoactive drugs.

15.

Patients who are taking indocin, anticoagulants,
antidiabetics, phenytoin, pheylbutazone.
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APPENDIX B
SICKNESS IMPACT PROFILE
BODY CARE AND MOVEMENT SUBSCALE
Sample Items:
1.

I do not maintain balance.

2.

I stay lying down most of the time.

3.

I do not bathe myself completely, for example, require
asistance with bathing.

4.

I have trouble getting shoes, socks,

or stockings on.

5.

I stand only for short periods of time.
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APPENDIX C
PSYCHOSOCIAL ADJUSTMENT TO ILLNESS- SELF REPORT
SEXUAL FUNCTIONING SUBSCALE
Sample Items;
1.

Sometimes when people are ill they report a loss of
interest in sexual activities. Have you experienced
less sexual interest since your illness?
a) absolutely no sexual interest since illness
b) a marked loss of sexual interest
c) a slight loss of sexual interest
d) no loss of sexual interest
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APPENDIX D
UNIFIED PARKINSON'S DISEASE RATING SCALE
Sample i.
t,em:
1.

Tremor at rest
0 = absent
1 = slight and infrequently present
2 = mild in amplitude and present most of the time
3 = moderate in amplitude and present most of the time

Face, lips, chin--------Right arm

---------

Left arm

---------

Right leg

---------

Left leg

---------
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APPENDIX E
HOEHN AND YAHR
DISEASE SEVERITY RATING

STAGE

0

no signs of PD

1.0

unilateral involvement only-

1.5

unilateral and axial involvement

2.0

bilateral involvement without
impairment of balance

2.5

mild bilateral involvement with
recovery on retropulsion

3 .0

mild to moderate bilateral
involvement some postural
instability but physically
independent

4 .0

Severe disability, still able to
walk or stand unassisted

5 .0

Wheelchair bound or bedridden
unless aided.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

APPENDIX F
DEMOGRAPHIC QUESTIONNAIRE

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

97

APPENDIX F
DEMOGRAPHIC QUESTIONNAIRE

D ATE:__________
P T . CODE:__________

1.

Sex: Female

2.

Date of Birth:____________

3.

Male____

Marital Status: Single_
Divorced/Separated_

Married_________
Widowed________

4.

Year Parkinson's Disease was Diagnosed:____________

5.

Education:

(Circle HighestYear Completed)

Elementary thru High School 1 2 3 4 5 6 7 8 9
College 13 14 15 16
6.

Presently Employed

10 11 12

Graduate 17
Retired

Seeking Work____

PATIENT: PLEASE LEAVE QUESTIONS BELOW BLANK

Hoehn and Yahr:

"ON"__________

Total Motor UPDRS:

Pre

"OFF"_
Post
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